trivalent mrkad5 hiv-1 gag/pol/nef
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2003 (NCT00849680)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- trivalent mrkad5 hiv-1 gag/pol/nef
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00095576 | Phase 2 | Nov 1, 2004 | HIV Vaccine Trials Network, Merck |
| NCT00849680 | Phase 1 | Apr 1, 2003 | Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 2 | 2003 |
| HIV Vaccine Trials Network | Academic/Hospital | 1 | 0 | 1 | 2004 |
2 organizations
Page 1 / 1